HeartWare Schedules First Quarter 2015 Conference Call And Webcast
PR Newswire - Wed Apr 22, 12:00PM CDT
HeartWare International, Inc. (NASDAQ:HTWR) has scheduled a conference call to discuss its financial results for the three months ended March 31, 2015, at 8:00 a.m. U.S. ET on Thursday, April 30, 2015. The Company plans to release the financial results prior to the conference call.
HTWR: 77.60 (-2.35)
Thoratec Announced Study Results, Time To Book Profit?
Andy Batts - at Seeking Alpha - Wed Apr 22, 7:34AM CDT
THOR: 43.00 (-0.76), HTWR: 77.60 (-2.35)
InsiderInsights.com Daily Round Up 4/21/15: HTWR, ASYS, BH, NXRT
InsiderInsights - at Seeking Alpha - Wed Apr 22, 5:08AM CDT
IMDZ: 26.66 (+0.22), AGCO: 48.16 (-0.16), SAM: 261.44 (-2.60), NXRT: 13.95 (+0.01), GDL: 10.41 (+0.04), MRD: 19.19 (+0.06), HTWR: 77.60 (-2.35), ASYS: 12.01 (+0.40), MS: 37.20 (+0.45), VIRT: 21.81 (-0.54), BH: 396.99 (-5.47), LNKD: 259.35 (+0.93), EVTC: 21.61 (+0.38), CDTX: 14.94 (-0.11), NEOG: 47.09 (-0.51), HRG: 12.15 (+0.02)
How it All Plays Out: Complementary Research on ForceField Energy, TCP International, Vimicro International, Dot Hill Systems, and Heartware International
PR Newswire - Tue Apr 21, 9:18AM CDT
Editor Note: For more information about this release, please scroll to bottom.
HILL: 6.52 (+0.11), FNRG: 3.11 (-0.86), TCPI: 3.85 (-0.13), VIMC: 13.42 (+1.31), HTWR: 77.60 (-2.35)
Contemporary Results From Commercial HVAD® System Registries Highlighted At ISHLT Meeting In Nice, France
PR Newswire - Mon Apr 20, 3:30PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today commented on results from multi-center commercial HVAD® System registries presented and discussed at the 35th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting in Nice, France.
HTWR: 77.60 (-2.35)
HeartWare International Falls 3.27% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Apr 16, 4:50PM CDT
HeartWare International (NASDAQ:HTWR) traded in a range yesterday that spanned from a low of $82.02 to a high of $86.91. Yesterday, the shares fell 3.3%, which took the trading range below the 3-day low of $86.89 on volume of 939,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
HTWR: 77.60 (-2.35)
HeartWare Achieves Primary Endpoint In The ENDURANCE Destination Therapy Clinical Trial
PR Newswire Europe - Thu Apr 16, 3:23AM CDT
Investigators Report Data from First Cohort in Destination Therapy at the 35(th) Annual International Society for Heart and Lung Transplantation Meeting in Nice, France
HTWR: 77.60 (-2.35)
Shares of HTWR Up 14.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 15, 4:54PM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on January 6th, 2015 at $76.40. In approximately 3 months, HeartWare International has returned 14.20% as of today's recent price of $87.24.
HTWR: 77.60 (-2.35)
HeartWare Gets VAD Distribution Approval from Health Canada - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 15, 12:00PM CDT
HeartWare International Inc. (HTWR) recently received approval from Health Canada to market its HVAD as a bridge to heart transplantation in patients with end-stage heart failure conditions.
ABMD: 69.31 (-0.40), THOR: 43.00 (-0.76), LMNX: 16.34 (-0.01), HTWR: 77.60 (-2.35)
HeartWare Announces Webcasts At The 35th International Society for Heart and Lung Transplantation Annual Meeting
PR Newswire - Fri Apr 10, 6:00PM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced it will webcast two events at the 35th International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting and Scientific Sessions in Nice, France on Thursday, April 16, 2015.
HTWR: 77.60 (-2.35)
HeartWare International Receives Health Canada Approval For Commercialization Of The HeartWare® Ventricular Assist System As A Bridge To Heart Transplantation
PR Newswire - Thu Apr 09, 6:30AM CDT
HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced that it has received approval from Health Canada, the country's federal department responsible for helping Canadians maintain their health, to market the HeartWare® Ventricular Assist System as a bridge to heart transplantation in patients with end-stage heart failure.
HTWR: 77.60 (-2.35)
BUYINS.NET: DTO, HTWR, ITR, IEI, HF, FIG Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Wed Apr 08, 7:01AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of POWERSHARES DB OIL 2X SHORT (NYSE
HF: 40.68 (+0.49), IEI: 124.02 (-0.37), FIG: 8.23 (-0.05), ITR: 34.59 (-0.08), DTO: 77.26 (+1.46), BWZ: 30.46 (+0.05), IEI.VN: 4.850 (unch), HTWR: 77.60 (-2.35)
Insider Trading Alert - CNMD, DST And HTWR Traded By Insiders
at The Street - Mon Apr 06, 11:07AM CDT
Stocks with insider trader activity include CNMD, DST and HTWR
CNMD: 49.35 (+0.36), HTWR: 77.60 (-2.35), DST: 116.35 (+0.44)
16.3% Return Seen to Date on SmarTrend HeartWare International Call (HTWR)
Comtex SmarTrend(R) - Fri Mar 27, 11:46AM CDT
SmarTrend identified an Uptrend for HeartWare International (NASDAQ:HTWR) on January 6th, 2015 at $76.40. In approximately 3 months, HeartWare International has returned 16.32% as of today's recent price of $88.86.
HTWR: 77.60 (-2.35)
Sunshine Clouds Over After Patient Deaths
EP Vantage - at Seeking Alpha - Mon Mar 09, 2:24PM CDT
Suspending a pivotal trial is always a worry. When it is a trial of a company’s sole device, and the halt is due to four of the first 20 patients enrolled dying, it is more than a worry. Shares in Sunshine Heart (NASDAQ: SSH ) fell 25% on...
SSH: 4.18 (+0.04), THOR: 43.00 (-0.76), HTWR: 77.60 (-2.35)
Heartware International Posts Q4 Loss; MVAD Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 06, 9:40AM CST
Heartware International Inc. (HTWR) believes that its new miniaturized ventricular assist device (MVAD) will help it gain market traction in 2015 and beyond.
ABMD: 69.31 (-0.40), THOR: 43.00 (-0.76), LMNX: 16.34 (-0.01), HTWR: 77.60 (-2.35)